Data Foundry

Drug recalls 2022

Losartan potassium & Hydrochlorothiazide Tablets 100 mg/25 mg — Class II drug recall D-1164-2022

Terminated recall by Macleods Pharma Usa Inc, reported 2022-07-06, distributed nationwide. CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits

Recall numberD-1164-2022
Product typeDrug
ClassificationClass II
StatusTerminated
Voluntary or mandatedVoluntary
Recalling firmMacleods Pharma Usa Inc, Plainsboro, NJ, United States
Recall initiated2022-06-10
Classified2022-06-27
Reported by FDA2022-07-06
Terminated2024-05-23
DistributedNationwide (US)
Quantity84
Reason classescgmp, specification failure
NDC33342-0050, 33342-0050-07, 33342-0050-10, 33342-0050-12, 33342-0050-44, 33342-0051, 33342-0051-07, 33342-0051-10, 33342-0051-12, 33342-0051-44, 33342-0052, 33342-0052-07, 33342-0052-10, 33342-0052-12, 33342-0052-44
Lot numbersBLM2114A
Expiration dates2023-07

Product

Losartan potassium & Hydrochlorothiazide Tablets 100 mg/25 mg, 30, 90 & 1000 count NDC # 33342-052-07, NDC #33342-052-10 & NDC # 33342-052-44, Rx Only, MFR: Macleods Pharma USA, Inc. Plainsboro, NJ 08536

Reason for recall

CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1164-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.